FDA Clears Roche Elecsys pTau217 Blood Test for Alzheimer's Detection

The FDA has cleared Roche's Elecsys pTau217 blood test for detecting amyloid pathology associated with Alzheimer's disease in adults aged 55 and older, marking the first single-biomarker blood test supporting both rule-in and rule-out assessments. The test integrates with existing Roche laboratory instruments, enabling broad access and potentially addressing the large diagnosis gap in dementia.

This Wire brief sits within Fusion42's coverage of Medtech, and 4 sources have reported it.